Evidence map›Paper›PMID 31058252›Full record

ArticleJCO precision oncology2018

Biological Validation of RNA Sequencing Data from Formalin-Fixed Paraffin-Embedded Primary Melanomas.

Lawrence N Kwong, Mariana Petaccia De Macedo, Lauren Haydu, Aron Y Joon, Michael T Tetzlaff, Tiffany L Calderone, Chiang-Jun Wu, Man Kam Kwong, Jason Roszik, Kenneth R Hess and 3 more

Abstract read
In one paragraph

Article in JCO precision oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Comprehensive Immunogenomic Profiling ofJCO precision oncology · 2024
    Article
  9. Multiplatform Analysis of Intratumoral PTEN Heterogeneity in Melanoma.The Journal of investigative dermatology · 2023
    Article
  10. Article
  11. Genomic Correlates of Outcome in Tumor-Infiltrating Lymphocyte Therapy for Metastatic Melanoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Distribution pattern of tumor infiltrating lymphocytes and tumor microenvironment composition as prognostic indicators in anorectal malignant melanoma.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2021
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Lawrence N KwongDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Mariana Petaccia De MacedoDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Lauren HayduDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Aron Y JoonDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX.
Michael T TetzlaffDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Tiffany L CalderoneDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Chiang-Jun WuDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
Man Kam KwongDepartment of Applied Mathematics, Hong Kong Polytechnic University, Hong Kong, China.
Jason RoszikDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Kenneth R HessDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX.
Michael A DaviesDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Alexander J LazarDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Jeffrey E GershenwaldDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
UT M.D. Anderson Cancer Center SPORE in MelanomaP50CA093459 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI GRIMM, ELIZABETH A · 2004 to 2014
$23.7M
NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA093459
6 · The paper itself

Abstract

purposeInitiatives such as The Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) have generated high-quality, multi-platform molecular data from thousands of frozen tumor samples. While these initiatives have provided invaluable insight into cancer biology, a tremendous potential resource remains largely untapped in formalin-fixed, paraffin-embedded (FFPE) samples that are more readily available, but which can present technical challenges due to crosslinking of fragile molecules such as RNA. MATERIALS AND

methodsWe extracted RNA from FFPE primary melanomas and assessed two gene expression platforms -- genome-wide RNA sequencing (RNA-seq) and targeted NanoString -- for their ability to generate coherent biological signals. To do so, we generated an improved approach to quantifying gene expression pathways, in which we refine pathway scores through correlation-guided gene subsetting. We also make comparisons to the TCGA and other publicly available melanoma datasets.

resultsComparison of the gene expression patterns to each other, to established biological modules, and to clinical and immunohistochemical data confirmed the fidelity of biological signals from both platforms using FFPE samples to known biology. Moreover, correlations with patient outcome data were consistent with previous frozen-tissue-based studies.

conclusionFFPE samples from previously difficult-to-access cancer types - such as small primary melanomas - represents a valuable and previously unexploited source of analyte for RNA-seq and NanoString platforms. This work provides an important step towards the use of such platforms to unlock novel molecular underpinnings and inform future biologically-driven clinical decisions.

Identifiers

PMID31058252
PMCPMC6498859

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.